相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Optimal Meropenem Concentrations To Treat Multidrug-Resistant Pseudomonas aeruginosa Septic Shock
Fabio Silvio Taccone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe
R. Canton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli
Michael Hombach et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Multiplex Real-Time PCR Assay for Detection and Classification of Klebsiella pneumoniae Carbapenemase Gene (blaKPC) Variants
Liang Chen et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
Pharmacokinetic-Pharmacodynamic- Model-Guided Doripenem Dosing in Critically Ill Patients
Mahesh N. Samtani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients
Yoshiaki Yamada et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Doripenem Pharmacokinetics in Critically III Patients Receiving Continuous Hemodiafiltration (CHDF)
Seigo Hidaka et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2010)
Characteristics of doripenem: a new broad-spectrum antibiotic
Francisco Alvarez-Lerma
Drug Design Development and Therapy (2010)
Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis
K. G. Naber et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Doripenem Monohydrate, A Broad-Spectrum Carbapenem Antibiotic
S. James Matthews et al.
CLINICAL THERAPEUTICS (2009)
Pharmacokinetic issues for antibiotics in the critically ill patient
Jason A. Roberts et al.
CRITICAL CARE MEDICINE (2009)
Activity of a novel carbapenem, doripenem, against anaerobic pathogens
Ellie J. C. Goldstein et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
Overview of Seizure-Inducing Potential of Doripenem
George G. Zhanel et al.
DRUG SAFETY (2009)
Doripenem: position in clinical practice
Harakh V. Dedhia et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2009)
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates
Sara Marti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Ertapenem peritoneal fluid concentrations in adult surgical patients
Silvia Arrigucci et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK
Michel Doumith et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Relevance of resistance levels to carbapenems and integron-borne blaIMP-1, blaIMP-7, blaIMP-10 and blaVIM-2 in clinical isolates of Pseudomonas aeruginosa
Wei-Hua Zhao et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2009)
Meta-analysis: ertapenem for complicated intra-abdominal infections
M. E. Falagas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men
Iolanda Cirillo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group
David R. Snydman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa
Todd A. Davies et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Parenteral carbapenems
P. M. Shah
CLINICAL MICROBIOLOGY AND INFECTION (2008)
New developments in carbapenems
J. N. Kattan et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study
Christopher Lucasti et al.
CLINICAL THERAPEUTICS (2008)
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia:: a randomized, open-label, multicenter study
Alvaro Rea-Neto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results
Philip J. Turner
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Doripenem A Review of its Use in the Treatment of Bacterial Infections
Susan J. Keam
DRUGS (2008)
The Pharmacokinetics and Pharmacodynamics of Meropenem in the Cerebrospinal Fluid of Neurosurgical Patients
R. Tsumura et al.
JOURNAL OF CHEMOTHERAPY (2008)
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis
Philipp Latzin et al.
JOURNAL OF CYSTIC FIBROSIS (2008)
Clinical review: Balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use
Thomas G. Slama
CRITICAL CARE (2008)
Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis
Kim L. Credito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Carbapenems: a potent class of antibiotics
David P. Nicolau
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients
Kazuro Ikawa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Continuous infusion of beta-lactams
Johan W. Mouton et al.
CURRENT OPINION IN CRITICAL CARE (2007)
Carbapenems in the USA: focus on doripenem
Philip D. Lister
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)
Diffusion of ertapenem into bone and synovial tissues
E. Boselli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Carbapenemases:: the versatile β-lactamases
Anne Marie Queenan et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model
C. Andrew DeRyke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia
I. I. Siempos et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps
Christine T. Ong et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Comparative review of the carbapenems
George G. Zhanel et al.
DRUGS (2007)
Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia
Emmanuel Boselli et al.
INTENSIVE CARE MEDICINE (2006)
Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia - a double blind prospective multicentre study
D. V. Schmitt et al.
INFECTION (2006)
Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase
JY Kim et al.
MOLECULAR MICROBIOLOGY (2006)
Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics
Masahito Horiuchi et al.
TOXICOLOGY (2006)
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa -: The high potency of a new carbapenem doripenem
Shihomi Sakyo et al.
JOURNAL OF ANTIBIOTICS (2006)
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention
AS Dela Pena et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2006)
Intraabdominal tissue concentration of ertapenem
M Wittau et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials
M Paul et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli
L Lorente et al.
ANNALS OF PHARMACOTHERAPY (2006)
Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia
Sungmin Kiem et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis
Olaf Burkhardt et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia
Maniari Joshi et al.
RESPIRATORY MEDICINE (2006)
Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)
TR Fritsche et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem
JE Conte et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial
BA Lipsky et al.
LANCET (2005)
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis
JL Blumer et al.
CHEST (2005)
Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically Ill patients
DN Fish et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery
O Burkhardt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis
A Novelli et al.
CLINICAL PHARMACOKINETICS (2005)
Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man
BK Wong et al.
XENOBIOTICA (2004)
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases
S Mushtaq et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro antimicrobial activity of doripenem, a new carbapenem
YG Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Newer carbapenems for urinary tract infections
T Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2004)
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of year five (2003)
PR Rhomberg et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Doripenem (S-4661), a novel carbapenem:: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
RN Jones et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae
DS Burgess et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers
T Laethem et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study
M West et al.
CLINICAL THERAPEUTICS (2003)
Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa:: comparison of in vitro and animal models
M Tsuji et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Carbapenems in the treatment of severe community acquired pneumonia in hospitalized elderly patients: A comparative study against standard therapy
G Romanelli et al.
JOURNAL OF CHEMOTHERAPY (2002)
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia
N Vetter et al.
CLINICAL THERAPEUTICS (2002)
Pharmacokinetics of ertapenem in healthy young volunteers
AK Majumdar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults
AE Yellin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: Results of a prospective, randomized, double-blind multicenter study
KM Tomera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults
F Jimenez-Cruz et al.
UROLOGY (2002)
Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections
BA Pelak et al.
JOURNAL OF CHEMOTHERAPY (2002)
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study
DR Graham et al.
CLINICAL INFECTIOUS DISEASES (2002)
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults
G Ortiz-Ruiz et al.
CLINICAL INFECTIOUS DISEASES (2002)
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections
KG Naber et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Meropenem and continuous renal replacement
F Thalhammer
CRITICAL CARE MEDICINE (2001)
In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
DM Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections
JS Solomkin et al.
ANNALS OF SURGERY (2001)
Treatment of severe nosocomial pneumonia:: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin
A Torres et al.
THORAX (2000)
Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy
F Thalhammer et al.
CLINICAL PHARMACOKINETICS (2000)
Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit
C Verwaest
CLINICAL MICROBIOLOGY AND INFECTION (2000)
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure
M Valtonen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Comparative pharmacokinetics of the carbapenems - Clinical implications
JW Mouton et al.
CLINICAL PHARMACOKINETICS (2000)
分享论文
